TY - JOUR T1 - Non-neutralizing secretory IgA and T cells targeting SARS-CoV-2 spike protein are transferred to the breastmilk upon BNT162b2 vaccination JF - medRxiv DO - 10.1101/2021.05.03.21256416 SP - 2021.05.03.21256416 AU - Juliana Gonçalves AU - A. Margarida Juliano AU - Nádia Charepe AU - Marta Alenquer AU - Diogo Athayde AU - Filipe Ferreira AU - Margarida Archer AU - Maria João Amorim AU - Fátima Serrano AU - Helena Soares Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/05/04/2021.05.03.21256416.abstract N2 - In view of data scarcity to guide decision-making in breastfeeding women, we evaluated how mRNA vaccines impact immune response of lactating health care workers (HCW) and the effector profile of breast milk transferred immune protection. We show that upon BNT162b2 vaccination, immune transfer via milk to suckling infants occurs through secretory IgA (SIgA) and T cells. Functionally, spike-SIgA was non-neutralizing and its titers were unaffected by vaccine boosting, indicating that spike-SIgA is produced in a T-cell independent manner by mammary gland. Even though their milk was devoid of neutralizing antibodies, we found that lactating women had higher frequencies of RBD-reactive circulating memory B cells and more RBD-IgG antibodies, when compared to controls. Nonetheless, blood neutralization titers in lactating and non-lactating HCW were similar. Further studies are required to determine transferred antibodies and spike-T cells complete functional profile and whether they can mediate protection in the suckling infant.HighlightsMilk and blood responses to BNT162b2 vaccine are initially isotype discordantImmune transfer via milk to suckling infants occurs by spike-reactive SIgA and T cellsSpike-reactive SIgA in the breastmilk is non-neutralizing and T-cell independentLactating vs non-lactating HCW had distinct cellular responses, despite similar NT50Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by ESCMID and by Gilead Génese (PGG/009/2017) grants to HS, RESEARCH4COVID 19 (Ref 580) to MJA, EU H2020 projects No. 823780 and 871037 (iNEXT-Discovery) to MA, and by Fundação para a Ciência e Tecnologia (FCT) through Project MOSTMICRO-ITQB with refs UIDB/04612/2020 and UIDP/04612/2020 to MA and DA. JG, DA, MJA and HS are supported by Fundação para a Ciência e Tecnologia (FCT) through PD/BD/128343/2017, BD/147987/2019, CEECIND/02373/2020 and CEECIND/2020/01049, respectively.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study has been approved by NOVA Medical School ethics committee, in accordance with the provisions of the Declaration of Helsinki and the Good Clinical Practice guidelines of the International Conference on Harmonization.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data will be made available upon request ER -